Evidence map›Paper›PMID 35710482›Full record

ArticleMicrobial cell factories2022

Astaxanthin and eicosapentaenoic acid production by S4, a new mutant strain of Nannochloropsis gaditana.

Michela Cecchin, Stefano Cazzaniga, Flavio Martini, Stefania Paltrinieri, Simone Bossi, Massimo E Maffei, Matteo Ballottari

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Harnessing microalgae for bioproducts: innovations in synthetic biology.World journal of microbiology & biotechnology · 2025
    Review
  2. Marine drugs · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michela CecchinDipartimento di Biotecnologie, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy.
Stefano CazzanigaDipartimento di Biotecnologie, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy.
Flavio MartiniDipartimento di Biotecnologie, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy.
Stefania PaltrinieriDipartimento di Biotecnologie, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy.
Simone BossiDipartimento di Scienze della Vita e Biologia dei Sistemi, Unità di Fisiologia Vegetale, Università di Torino, Via Quarello 15/a, 10135, Turin, Italy.
Massimo E MaffeiDipartimento di Scienze della Vita e Biologia dei Sistemi, Unità di Fisiologia Vegetale, Università di Torino, Via Quarello 15/a, 10135, Turin, Italy.
Matteo BallottariDipartimento di Biotecnologie, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy. matteo.ballottari@univr.it.
University of Verona · ITUniversity of Turin · IT

Funding

H2020 European Research Council 825936
6 · The paper itself

Abstract

backgroundAstaxanthin is a ketocarotenoid with high antioxidant power used in different fields as healthcare, food/feed supplementation and as pigmenting agent in aquaculture. Primary producers of astaxanthin are some species of microalgae, unicellular photosynthetic organisms, as Haematococcus lacustris. Astaxanthin production by cultivation of Haematococcus lacustris is costly due to low biomass productivity, high risk of contamination and the requirement of downstream extraction processes, causing an extremely high price on the market. Some microalgae species are also primary producers of omega-3 fatty acids, essential nutrients for humans, being related to cardiovascular wellness, and required for visual and cognitive development. One of the main well-known producers of omega-3 fatty eicosapentaenoic acid (EPA) is the marine microalga Nannochloropsis gaditana (named also Microchloropsis gaditana): this species has been already approved by the Food and Drug Administration (FDA) for human consumption and it is characterized by a fast grow phenotype.

resultsHere we obtained by chemical mutagenesis a Nannochloropsis gaditana mutant strain, called S4, characterized by increased carotenoid to chlorophyll ratio. S4 strain showed improved photosynthetic activity, increased lipid productivity and increased ketocarotenoids accumulation, producing not only canthaxanthin but also astaxanthin, usually found only in traces in the WT strain. Ketocarotenoids produced in S4 strain were extractible in different organic solvents, with the highest efficiency observed upon microwaves pre-treatment followed by methanol extraction. By cultivation of S4 strain at different irradiances it was possible to produce up to 1.3 and 5.2 mgL

conclusionsBy chemical mutagenesis and selection of strain with increased carotenoids to chlorophyll ratio it was possible to isolate a new Nannochloropsis gaditana strain, called S4 strain, characterized by increased lipids and ketocarotenoids accumulation. S4 strain can thus be considered as novel platform for ketocarotenoids and EPA production for different industrial applications.

Indexed as

MicroalgaeStramenopilesCarotenoidsChlorophyllEicosapentaenoic AcidXanthophyllsastaxanthineCarotenoidsChlorophyllEicosapentaenoic AcidXanthophyllsAstaxanthinCarotenoidsEicosapentaenoic acidMicroalgaeOmega-3 fatty acids

Identifiers

PMID35710482
PMCPMC9204945
OpenAlexW4283024519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.